$MANKIND Strategic R&D Subsidiary & Non-Core Divestment In July 2026, Mankind’s Board approved the incorporation of a wholly-owned subsidiary in the Netherlands (with an initial outlay of up to €5 million) to hold research assets and pursue international joint ventures in niche therapeutic areas. Concurrently, the company signed a share purchase agreement to divest its 100% stake in non-core hospitality asset Broadway Hospitality Services for ₹49 crore, focusing resources entirely on core pharmaceutical operations. Full-Year FY26 Financial Base & Q1 FY27 Earnings Date For the full financial year 2025–26, Mankind recorded a 17% year-on-year revenue expansion to ₹14,278 crore. In its preceding Q4 FY26 performance, consolidated net profit rose 30.3% YoY to ₹554 crore on revenue of ₹3,443 crore (+11.8% YoY). The company has formally scheduled its Board meeting and earnings conference call for July 30, 2026, to approve and discuss its Q1 FY27 financial performance. Synergy Rollout from BSV & Chronic Portfolio Push The ongoing integration of Bharat Serums and Vaccines (BSV) remains central to the group's mid-term operating model, driving margin expansion toward management's ~26% EBITDA target. Outpacing the overall Indian Pharmaceutical Market (IPM), Mankind’s domestic formulations segment logged double-digit volume growth, led by anti-diabetic and cardiovascular portfolios alongside entry into chronic and metabolic therapy lines.

#StockInNews#WatchOutFor#FundamentalViews#TechnicalViews#PersonalFinance

605 likes·74 comments